stockportfolio.pro
Arrowhead Pharmaceuticals, Inc. (ARWR)
Healthcare · Biotechnology · NasdaqGS
Arrowhead Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $158,333 | $31.41M | $16.14M | $168.80M | $87.99M | $138.29M | $243.23M | $240.74M | $3.55M | $829.45M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-81.72M | $-34.38M | $-54.45M | $67.97M | $-84.55M | $-140.85M | $-176.06M | $-205.28M | $-599.49M | $-1.63M |
| Net margin | -51614.6% | -109.5% | -337.3% | 40.3% | -96.1% | -101.9% | -72.4% | -85.3% | -16882.4% | -0.2% |
Source: Arrowhead Pharmaceuticals, Inc. SEC filings (10-K). 23 years of history available in the interactive view.
Explore 23 years of Arrowhead Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ARWR in your portfolio →
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals, Inc. — frequently asked questions
What is Arrowhead Pharmaceuticals, Inc.'s revenue?
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $829.45M for fiscal year 2025, up 23258.2% from the prior year, according to its SEC filings.
Is Arrowhead Pharmaceuticals, Inc. profitable?
No — ARWR reported a net loss of $-1.63M in fiscal 2025.
What is ARWR's P/E ratio?
Arrowhead Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Arrowhead Pharmaceuticals, Inc. growing?
ARWR's revenue grew at roughly 56.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Arrowhead Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 23 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.